Skip to search formSkip to main contentSkip to account menu

Enoxaparin

Known as: Enoxaparin [Chemical/Ingredient], Enoxaparine 
A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin… 
National Institutes of Health

Related topics

Related topics

30 relations
0.4 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe0.6 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe [Lovenox]0.8 ML Enoxaparin sodium 100 MG/ML Prefilled Syringe [Lovenox]Angina, Unstable

Broader (2)

AnticoagulantsFibrinolytic Agents

Narrower (5)

ClexaneEMT-966Enoxaparin sodiumLovenox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Progressive thrombocytopenia after cardiac surgery in a 67-year-old man
A 67-year-old man who had undergone uncomplicated bioprosthetic replacement of the aortic valve and coronary artery bypass… 
2012
2012
Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
Summary Edoxaban is an oral direct factor (F)Xa inhibitor in advanced stages of clinical development. The primary objective of… 
Review
2008
Review
2008
Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients
Drug utilization evaluation (DUE) is an effective program to identify variability in drug use and to support interventions that… 
Review
2006
Review
2006
Use of Low‐Molecular‐Weight Heparin to Bridge Therapy in Obese Patients and in Patients with Renal Dysfunction
Objective. To recommend strategies to bridge therapy with low‐molecular‐weight heparin (LMWH) in obese patients and in patients… 
2006
2006
A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004).
4110 Background: Approximately 20% of patients (pts) diagnosed with pancreatic adenocarcinoma (PA) develop venous thromboembolism… 
2005
2005
Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss
Summary Recurrent pregnancy loss (PL) is associated with maternal thrombophilia and prophylaxis with low molecular weight heparin… 
Highly Cited
2004
Highly Cited
2004
Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment
The use of weight-adjusted enoxaparin dosage in patients with renal failure results in increased bleeding complications. The… 
2003
2003
Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
BACKGROUND Heparin inhibits prothrombotic tissue factor (TF) and releases its inhibitor, tissue factor pathway inhibitor (TFPI… 
Highly Cited
2002
Highly Cited
2002
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
OBJECTIVE To determine the cost and cost effectiveness of adding venous thromboembolism (VTE) prophylaxis with enoxaparin, a low… 
1999
1999
Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes.
OBJECTIVE To determine whether heparin or the low-molecular-weight heparin enoxaparin alter lipopolysaccharide (LPS)-induced… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)